Celia Henry Arnaud, C&EN senior editor, points out that the U.S. Food and Drug Administration has approved several precedent-setting cancer drugs that provide a glimpse of the "personalized" medical care that awaits patients with cancer and other diseases in the future.
Personalized medicine involves selecting treatments that work best with the set of genes present in each individual person. Such treatments work only for patients with conditions related to mutations, or alterations, in certain genes.
The article describes new "companion diagnostics," or diagnostic tests that already have gone into use, with more on the horizon, to identify patients most likely to benefit from a medication. Doctors must perform these tests before starting treatment. Arnaud describes how pharmaceutical companies are embracing an approach that involves co-development of drugs and companion diagnostics that can be used in clinical trials and later when a medication goes into general use.
The American Chemical Society is a nonprofit organization chartered by the U.S. Congress. With more than 164,000 members, ACS is the world's largest scientific society and a global leader in providing access to chemistry-related research through its multiple databases, peer-reviewed journals and scientific conferences. Its main offices are in Washington, D.C., and Columbus, Ohio.
To automatically receive news releases from the American Chemical Society, contact email@example.com.
Michael Bernstein | EurekAlert!
New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia
New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular
16.08.2017 | Event News
04.08.2017 | Event News
26.07.2017 | Event News
18.08.2017 | Life Sciences
18.08.2017 | Physics and Astronomy
18.08.2017 | Materials Sciences